Xilio Therapeutics grants 177,000 RSUs to CEO and 20,000 RSUs to SVP in annual equity awards

Xilio Therapeutics, Inc.

CEO René Russo granted 177,000 restricted stock units effective Jan 1, 2024.
SVP Kevin Brennan granted 20,000 restricted stock units effective same date.
RSUs vest in four equal annual installments beginning Jan 1, 2025, subject to continued service.
Awards granted under 2021 Stock Incentive Plan; form agreement filed as Exhibit 10.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.